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Abstract
Background: Angiogenesis is a hallmark of cancer and plays a critical role in lung cancer progression, which
involves interactions between cancer cells, endothelial cells and the surrounding microenvironment. However, the
gene expression profiles and the changes in the biological phenotype of vascular endothelial cells after interactions
with lung cancer cells remain unclear.
Methods: An indirect transwell co-culture system was used to survey the interaction between human umbilical
vein endothelial cells (HUVECs) and human lung adenocarcinoma CL1-5 cells, as well as to investigate the
morphological and molecular changes of HUVECs. The differentially expressed genes (DEGs) in HUVECs after
co-culture with cancer cells were identified by microarray. Moreover, a publicly available microarray dataset of 293
non-small-cell lung cancer (NSCLC) patients was employed to evaluate the prognostic power of the gene
signatures derived from HUVECs.
Results: The interaction between HUVECs and lung cancer cells changes the morphology of HUVECs, causing them
to have a mesenchymal-like morphology and alter their cytoskeleton organization. Furthermore, after co-culture
with lung cancer cells, HUVECs showed increased cell motility and microvessel tube formation ability and a
decreased apoptotic percentage. Transcriptomic profiling of HUVECs revealed that many survival-, apoptosis- and
angiogenesis-related genes were differentially expressed after interactions with lung cancer cells. Further
investigations showed that the PI3K/Akt signalling pathway and COX-2 are involved in endothelial tube formation
under the stimulation of lung cancer cells. Moreover, Rac-1 activation might promote endothelial cell motility
through the increased formation of lamellipodia and filopodia. The inhibitors of PI3K and COX-2 could reverse the
increased tube formation and induce the apoptosis of HUVECs. In addition, the gene signatures derived from the
DEGs in HUVECs could predict overall survival and disease-free survival in NSCLC patients and serve as an
independent prognostic factor.
Conclusions: In this study, we found that cancer cells can promote endothelial cell tube formation and survival, at
least in part, through the PI3K/Akt signalling pathway and thus change the microenvironment to benefit tumour
growth. The gene signatures from HUVECs are associated with the clinical outcome of NSCLC patients.
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Background
The process by which new blood vessels sprout from
pre-existing blood vessels is called angiogenesis. This
step is normal and important in wound healing, cell
growth and development [1]. However, angiogenesis is
also a prerequisite for tumour progression and metasta-
sis. Tumour angiogenesis provides oxygen and nutrients
to cancer cells and also provides a route for cancer cell
metastasis [2–4]. High tumour angiogenesis activity is
associated with advanced tumour growth and metastasis
in human cancers [5]. Moreover, the non-small-cell lung
cancer (NSCLC) patients with higher microvessel dens-
ities in tumour tissues have a worse survival [6, 7].
The tumour microenvironment is composed of tumour
cells, blood vessels, immune cells, fibroblasts and extracel-
lular matrix (ECM) [8]. Many investigations have shown
that the microenvironment plays a crucial role in tumour
growth, metastasis and angiogenesis. Particularly, the pro-
liferation and motility of endothelial cells are essential for
microvessel sprout formation and angiogenesis, which
correlates with cancer metastasis. The interaction between
cancer, endothelial cells and other components of the
microenvironment may have a reciprocal effect on angio-
genesis, cancer cell proliferation and dissemination [9].
Vascular endothelial growth factor (VEGF) is a key regula-
tor of angiogenesis. A previous meta-analysis showed that
VEGF overexpression in tumour indicates an unfavourable
prognosis in NSCLC patients [10]. Collagen VI, a major
ECM protein in the microenvironment, can induce angio-
genesis and promote tumour progression [11]. Cancer-
associated fibroblasts promote angiogenesis, invasion and
metastasis in many cancers [12, 13]. Tumour-associated
macrophages stimulate tumour progression by inducing
angiogenesis and suppressing adaptive immunity [14].
Our group also reported that M1-type macrophages could
reduce tumour growth and angiogenesis in vitro and in
vivo [15].
Dozens of studies have illustrated that the PI3K/Akt
signalling pathway is critical in tumour growth, prolifer-
ation and survival. This makes PI3K/Akt and down-
stream signalling components suitable therapeutic
targets [16, 17]. Moreover, several reports also show that
PI3K and Akt play crucial roles in endothelial cell sur-
vival and angiogenesis and activated by VEGF, fibroblast
growth factor (FGF) stimulation [18, 19]. However, the
actual mechanisms that regulate tumour angiogenesis
and cancer progression within the tumour microenvir-
onment remain unclear. Previous data showed that gli-
oma conditioned medium increased the proliferation,
migration and tube formation of human brain endothe-
lial cells via Roundabout4 (Robo4) down-regulation [20].
However, the mechanism behind the association be-
tween endothelial cells and lung cancer has not been
defined. Lung cancer is one of the top ten causes of
death in human malignancy and shows a poorer progno-
sis than other human cancers [21]. Therefore, the clarifi-
cation of the molecular mechanism is essential for the
discovery of new therapeutic reagents in the treatment
of NSCLC.
In this study, we identified the differentially expressed
genes of human endothelial cells after interaction with a
human lung cancer cell line through an indirect co-
culture system by microarray. A panel of genes involved
in migration, tube formation and apoptosis were identi-
fied and validated. Inhibitors of the key activated genes
(such as PI3K and COX-2) were applied to confirm the
effect of these activated genes on the angiogenesis of
endothelial cells after co-culture with lung cancer cells.
These results may provide new therapeutic targets for
anti-angiogenesis therapy for NSCLC in the future.
Methods
Cells
Human umbilical vein endothelial cells (HUVECs,
pooled donors) were obtained from Lonza (Walkersville,
MA) and maintained in Endothelial Basel Medium-2
(EBM-2) with supplements (Lonza). Replicated cultures
were obtained by trypsinization and were used at pas-
sages < 6. The human lung adenocarcinoma cell line
CL1-5 was established previously [22]. The cells were
grown in RPMI 1640 medium (Thermo Fisher Scientific,
Rockford, IL) supplemented with 10% FBS. All cell lines
were kept at 37 °C in a humidified atmosphere contain-
ing 5% CO2. The Transwell Permeable Supports
(Corning, Tewksbury, MA) with a 0.4 μm polycarbonate
membrane were used in the co-culture model system to
separate HUVECs and CL1-5 cells into the different
compartments. One hour prior to co-culture, 5 × 104
HUVECs in 500 μl EBM-2 were grown in 24-well plate
with or without Matrigel coating (BD Biosciences, San
Jose, CA). An equivalent number of CL1-5 cells in
200 μl EBM-2 were seeded into the top chamber of a
transwell insert, which was then placed directly on top
of the 24-well plate containing the HUVECs. When per-
forming tube formation and TUNEL assay, HUVECs
were seeded on Matrigel in 24-well plate. After incuba-
tion of overnight (mRNA and protein expression) or the
indicated time (tube formation and TUNEL assay),
HUVECs were harvested for further analysis as de-
scribed below. For the motility assay, the 8 μm polycar-
bonate membrane insert was used in the co-culture
system where HUVECs were in the upper and CL1-5
cells were in the lower compartment as described in the
migration assay section.
F-actin staining
For F-actin staining, cells were plated on 12-mm-diameter
coverslips for 24 h, washed twice with phosphate-buffered
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saline (PBS) and fixed in 4% paraformaldehyde for 10 min
at room temperature. After two additional washes with
PBS, cells were permeabilized with 0.1% Triton X-100 for
2–5 min and washed again with PBS. Rhodamine conju-
gates of Phalloidin (Thermo Fisher Scientific) were used
to stain F-actin. The cells were stained for 40 min at room
temperature. The nuclei were stained with 4',6-diamidino-
2-phenylindole (DAPI). The fluorescence images of F-
actin and nuclei were visualized by confocal microscopy
(ZEISS, Germany).
Migration assay
The Transwell Permeable Support (Corning) with an 8-
μm polycarbonate membrane insert was used in the cell
migration model where HUVECs were allowed to mi-
grate. Approximately 2 × 104 HUVECs in 200 μL EBM-2
medium were loaded into each 24-well insert in tripli-
cate with or without CL1-5 cells in the lower chamber at
37 °C in a 5% CO2 incubator. After approximately 20 h,
the migrated cells were fixed with methanol, stained
with Giemsa solution (Sigma, St. Louis, MO) and
counted at 200x magnification under a light microscope.
TUNEL assay
Detection and quantification of apoptosis were per-
formed by the TUNEL reaction, using the In Situ Cell
Death Detection Kit, Fluorescein (Roche Diagnostics, In-
dianapolis, IN). Cells were recovered from Matrigel by
Cell Recovery Solution (Corning) after culture for 6, 12,
24 and 30 h, seeded onto slides by cytospin and stained
following the standard protocol to label DNA strand
breaks with fluorescein-dUTP. Propidium iodide (PI)
was used to label all nuclei. The image data were ana-
lysed under a fluorescence microscope. Experiments
were evaluated in triplicate, and 10 fields of view were
quantified for each sample.
Tube formation
Matrigel Basement Membrane Matrix (BD Biosciences)
was diluted with EBM-2 medium and coated in 24-well
plates at 37 °C for 1 h. Then, 5 × 104 HUVECs were
seeded alone or co-cultured with an equivalent number
of CL1-5 cells in the EBM-2 medium on Matrigel. Co-
cultured CL1-5 cells were seeded in transwells and incu-
bated in the same well with HUVECs. The tube forma-
tion ability of HUVECs was measured at 1, 2, 6, 12 and
24 h with or without CL1-5 cells. In inhibitor experi-
ments, HUVECs were treated with the PI3K inhibitor
LY294002 (5 μM) and the COX-2 inhibitor celecoxib
(10 μM) (Sigma) for 12 h and co-cultured with CL1-5
cells. After incubation, the number of tubes and nodes
of the tubular structures was quantified.
Real-time quantitative PCR
Total RNA was extracted from HUVECs, which were
co-cultured with or without CL1-5 cells. First-strand
cDNA for real-time quantitative PCR (QPCR) analysis
was obtained from 5 μg of total RNA using a random
primer and SuperScript III Reverse Transcriptase kit
(Thermo Fisher Scientific) according to the manufac-
turer’s instructions. Reactions were detected by the
SYBR Green approach (Thermo Fisher Scientific). Ten
nanograms of cDNAs served as templates to detect gene
expression. Experiments were performed three times in
triplicate. Details of the specific primers designed for
QPCR to determine relative levels of gene expression are
shown in Table 1.
Western blot
All experiments were performed as previously described
[23]. After transfer to nitrocellulose membranes, the fol-
lowing primary antibodies were used: α-actinin (Merck
Millipore, Billerica, MA), β-catenin (SANTA CRUZ
Table 1 Primer sequences used in real-time PCR experiments
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BIOTECHNOLOGY, Dallas, Texas), Akt (Cell Signaling
Technology, Beverly, MA), phospho-Akt (Ser473) (Cell
Signaling Technology), PI3K (SANTA CRUZ BIOTECH-
NOLOGY), phospho-PI3K p85 (Tyr458)/p55 (Tyr199)
(Cell Signaling Technology), PARP (Cell Signaling Tech-
nology) and Caspase 3 (Cell Signaling Technology).
Chemiluminescent signals were detected by the Fujifilm
LAS-3000 system (Fujifilm, Tokyo, Japan), and β-actin
and α-tubulin (Sigma) (Merck Millipore) were used as
the loading control. To determine the Rac-1 activity, the
Active Rac1 Pull-Down and Detection Kit was used, ac-
cording to the manufacturer’s protocol (Thermo Fisher
Scientific).
Microarray analysis
The mRNA profiles of HUVECs co-cultured with or
without CL1-5 cells were analysed using the Affymetrix
Human Genome U133 Plus 2.0 GeneChip according to
the manufacturer’s protocols (Santa Clara, CA) by the
National Taiwan University Microarray Core Facility for
Genomic Medicine. The raw data were analysed by Gen-
eChip Operating software (GCOS). Pathway analyses of
the differentially expressed genes were performed using
the DAVID programme [24].
Statistical analysis
The data were presented as the means ± standard devia-
tions, and the significance of differences was analysed
using Student’s t-test. All experiments were performed
in triplicate. To evaluate the prognostic ability of the se-
lected candidate genes, we examined their association
with clinical data using a published microarray dataset
GSE30219 [25]. The intensity values of the probes from
expression profile of GSE30219 were first rescaled using
a quantile normalization method, and then log-
transformed to a base-2 scale. The prognostic test was
performed as previously described [15]. Briefly, the dif-
ferentially expressed genes were employed to test its as-
sociation with overall survival and disease-free survival
by univariate Cox proportional hazard regression ana-
lysis. For those genes with a significant Cox regression
coefficient, a risk score method was used to calculate the
signature and construct the risk score function. The risk
score function was a linear combination of gene expres-
sion weighted by the regression coefficient from Cox re-
gression. The median risk score was used as the cut-off
point for patient classification. Kaplan-Meier method
was used to estimate survival curve and difference be-
tween curves was evaluated by log-rank test. Multivari-
ate Cox proportional hazards regression analysis was
employed to evaluate independent prognostic factors,
and age, gender and stage were used as covariates. All
statistical tests were two-tailed and P < 0.05 was consid-
ered statistically significant.
Results
The phenotype of HUVECs changed after co-culture with
CL1-5 cells
To clarify the interaction between endothelial cells and
cancer cells, we established a co-culture system using
the Corning 0.4 μm polycarbonate membrane. In this
model, HUVECs were seeded in the lower chamber and
CL1-5 lung cancer cells were seeded in the upper com-
partment. This system was labelled as HUVEC/CL1-5 in
the figures, and HUVECs without cancer cells were la-
belled as HUVEC.
We used the phenotypic changes of HUVECs to evalu-
ate the effects of lung cancer cells on angiogenesis in the
co-culture system. The morphology of HUVECs alone
revealed a fusiform cell shape and formed a tight cluster.
In contrast, after co-culture with CL1-5 cells, the
HUVECs elongated, spread and lost contact with each
other, as shown in Fig. 1a.
Angiogenesis is a multi-step process that includes pro-
liferation, migration and tube formation of endothelial
cells. Endothelial cells migrate along chemoattractants,
which are secreted in the microenvironment. Here, we
used the transwell migration assay to create the chemical
gradient by putting cancer cells in the lower chamber.
The data also showed that the migration capacity of
HUVECs increased significantly (2.2-fold) when co-
cultured with CL1-5 cells compared with HUVECs alone
(P < 0.05) (Fig. 1b).
To evaluate the ability to undergo angiogenesis, the tube
formation experiment is the key method used in vitro.
When HUVECs were seeded on Matrigel, they gradually
formed capillary-like tubular structures, and the capillary-
like tubes connected to each other created a mesh-like
structure on the gel. The capillary-like tubular structure
was formed more densely, reached a peak at 2 h and fi-
nally disappeared in a time-dependent manner. Quantita-
tive analysis of capillary-like tubular structures showed
that the number of tubes and nodes significantly increased
when HUVECs were co-cultured with CL1-5 cells at each
time point (P < 0.05) (Fig. 1c). It appeared that the angio-
genic ability of HUVECs increased after co-culture with
cancer cells. On the other hand, the viability of endothelial
cells is also critical in tumour angiogenesis [26]. As shown
in Fig. 1c, the tubular structures decreased and the cell
death increased as time went by. To further investigate
whether the viability of HUVECs was altered by cancer
cells, TUNEL assay was performed at 6, 12, 24 and 30 h
after seeding HUVECs on Matrigel-coated plate. HUVECs
were recovered from Matrigel by Cell Recovery Solution
and estimated the apoptotic percentage. The percentages
of apoptotic HUVECs were low at 6 h and showed no dif-
ference between co-culture and non-co-culture groups.
However, the apoptotic percentage of HUVECs alone
was increased 1.5 ~ 2-fold higher than that of
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HUVECs co-culture with CL1-5 cells and in a time
dependent manner after 12, 24 and 30 h of tube
formation (P < 0.05) (Fig. 1d). This indicated that co-
culture with cancer cells would decrease the apoptotic
percentage of endothelial cells.
Gene expression and protein level changes in HUVECs
after co-culture with CL1-5 cells
As shown in Fig. 1, many phenotypes of HUVECs chan-
ged when co-cultured with cancer cells. To identify the
specific molecular mechanism, we used an Affymetrix
Fig. 1 Phenotype changes of HUVECs after co-culture with CL1-5 cells. a Cell morphology of HUVECs co-cultured with or without CL1-5 cells, as
determined by Giemsa Staining. Scale: 50 μm. b Migration ability and (d) apoptotic percentage of HUVECs after co-culture with CL1-5 cells, as
measured by transwell and TUNEL assays, respectively. Green: TUNEL-positive nuclei. Red: all nuclei. *P < 0.05 compared with HUVECs only. c Phase
contrast micrographs of the capillary-like tubular structures of HUVECs on Matrigel when cultured with or without CL1-5 cells for 1, 2, 6, 12, and
24 h. Bar graphs revealed the tube (upper panel) and node (lower panel) numbers (*P < 0.05). The data are presented as the mean ± SD.
Experiments were performed in triplicate. Magnification, x100. H: HUVECs alone; H/C: HUVECs co-cultured with CL1-5 cells
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microarray to identify the gene expression profile. We
found that ~7000 genes were up-regulated and down-
regulated over 2.5-fold in HUVECs co-cultured with
CL1-5 cells compared to HUVECs alone. The differen-
tially expressed genes were subjected to pathway analysis
using DAVID. The top 10 significant pathways are listed
in Additional file 1: Table S1. These functional pathways
provided us with useful hints to confirm the molecular
changes of HUVECs altered by cancer cells.
According to pathway organization, we identified
that PIK3CA, PIK3R3, AKT3, ITGAV, ITGB3 and
RAC1 appeared in the top 2nd, 4th and 5th pathways
(i.e., PI3K-Akt signalling pathway, Jak-STAT signalling
pathway and RAP1 signalling pathway, respectively)
and were correlated with the observed phenotypes.
Although the changes in the expression of PIK3R1
and CTNNB1 were under 2.5-fold, these genes were
also selected for further analysis due to their role in
these three pathways. Moreover, based on a reference
search, we further identified some genes enriched in
the lower ranking of DAVID that predicted functional
annotation or some genes with under a 2.5-fold
change but related to the phenotype change of
HUVECs, including ACTN1, PTGS2 (COX-2),
CXCL8, VCAM1 and ICAM1. These candidate genes
have been shown to be involved in survival, migration
and angiogenesis. The expression of these genes was
validated by QPCR, as shown in Fig. 2. In survival-
related genes (Fig. 2a), all of the investigated genes
were up-regulated in HUVECs with cancer cell co-
culture. Among these, the mRNA levels of PIK3R1
and CTNNB1 were increased more than 2-fold, and
those of PIK3R3, PIK3CA and AKT3 were increased
1.6- to 1.9-fold after co-culture with cancer cells.
Nevertheless, the expression of these genes exhibited
the same trend as the microarray data. In addition, all
of the migration- and angiogenesis-related genes in
HUVECs with CL1-5 co-culture were expressed 2-fold
more than the genes in HUVECs alone (Fig. 2b, c).
The comparison of the expression level between
microarray and QPCR was summarized in Additional
file 1: Table S2. The protein level and activity (phos-
phorylation status) were also confirmed by Western
blot and showed a significant increase after co-culture
with cancer cells (Fig. 3a, b).
Rac-1, lamellipodia and filopodia were activated to
promote cell motility in HUVECs after co-culture with
CL1-5 cells
Based on our results, the migration ability of
HUVECs was elevated after co-culture with cancer
cells (Fig. 1b). In cell migration, Rho GTPases are im-
portant regulators of cell cytoskeleton dynamics [27].
Here, we showed that Rac-1 was bound by GTP after
Fig. 2 Increased expression of survival-, migration- and angiogenesis-
related genes in HUVECs after co-culture with CL1-5 cells. The mRNA
expression levels of the selected genes from microarray analysis were
detected by QPCR. The fold changes of survival-related genes (a),
migration-related genes (b) and angiogenesis-related genes (c) in
HUVECs co-cultured with CL1-5 cells were calculated relative to the
HUVECs alone group and normalized to internal control TBP. The data
are presented as the mean ± SD. Experiments were performed in
triplicate. Gene name versus protein name: CTNNB1 vs. β–catenin;
ITGAV vs. integrin alpha 3; ITGB3 vs. integrin beta 3; ACTN1 vs. α-
actinin; RAC1 vs. Rac-1; PTGS2 vs. COX-2; CXCL8 vs. IL-8
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co-culture with CL1-5 cells (Fig. 3c). It revealed that
Rac-1 was activated in HUVECs after co-culture with
CL1-5, and this might contribute to the increasing
motility of HUVECs after interaction with lung cancer
cells.
Lamellipodia and filopodia are crucial in cell motility
[28–30]. During cell movement, protrusions are stimu-
lated at the leading edge of cells. We used rhodamine
phalloidin to stain and label cytoskeleton F-actin in
HUVECs and observed fluorescence images by confocal
microscopy. The results showed that the cell margin of
HUVECs alone group was smoother than that of the co-
culture group. The cytoskeletal distribution of F-actin in
HUVECs was rearranged after co-culture with CL1-5
cells. Filopodia stuck out of the lamellipodia (Fig. 3d). In
addition, the number of filopodia increased in HUVECs
after co-culture with CL1-5 cells (P < 0.05) (Fig. 3e).
PI3K and COX-2 inhibitors attenuated the capillary-like
tubular formation on Matrigel and promoted the
apoptosis of HUVECs after co-culture with CL1-5 cells
In previous data, PI3K and COX-2 expression were
significantly up-regulated in HUVECs after co-culture
with CL1-5 cells (Figs. 2 and 3a). These proteins were
reported to be involved in cell survival, migration and
angiogenesis. Therefore, we chose inhibitors of PI3K
(LY294002) and COX-2 (celecoxib) to clarify their ef-
fects on the capillary-like tubular formation capacity
and cell viability of HUVECs after co-culture with
CL1-5 cells. After being treated with 5 μM LY294002
and 10 μM celecoxib in HUVECs of the co-culture
system, the capillary-like tubular structure on Matri-
gel was reduced significantly at 12 h compared with
that of HUVEC/CL1-5 without inhibitor treatment.
The number of tubes and nodes were also decreased
Fig. 3 Protein changes and the F-actin distribution of HUVECs after co-culture with CL1-5 cells. a-c Immunoblots of the indicated proteins in
HUVECs after interactions with CL1-5 cells for 24 h. The active Rac-1 was determined by the Active Rac1 Pull-Down and Detection Kit. β-actin or
α-tubulin was used as the loading control. d Fluorescence images of lamellipodia and filopodia of HUVECs by F-actin staining. Scale: 20 μm and
10 μm (zoom in part). Red: F-actin. Blue: nuclear staining with DAPI. e The quantified number of filopodia of HUVECs co-cultured with CL1-5 cells
(*P < 0.05) (n = 5). H: HUVECs alone; H/C: HUVECs co-cultured with CL1-5 cells. The data are presented as the mean ± SD. Experiments were
performed in triplicate
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in HUVEC/CL1-5 with treatment with LY294002 and
celecoxib compared to the non-treated control (P <
0.05) (Fig. 4a). Furthermore, the apoptotic percentage
increased from 18% to 78% compared with the non-
treated control after LY294002 treatment by TUNEL
staining assay (P < 0.05) (Fig. 4b). This apoptosis
process involved Caspase 3 and PARP cleavage
(Fig. 4c). These data revealed that PI3K and COX-2
were important in endothelial cell angiogenesis and
survival. Manipulating PI3K and COX-2 could reverse
the phenotypic changes of HUVECs after co-culture
with lung cancer cells.
Cancer cell-stimulated gene signatures were associated
with the clinical outcome of NSCLC patients
The data mentioned above indicated that many genes in
endothelial cells were up-regulated after co-culture with
cancer cells and correlated with angiogenesis, migration
and anti-apoptosis phenotypes. Generally, the tumour
specimen may contain not only endothelial cells but also
surrounding tissue when the tumour section was dis-
sected. Thus, we sought to determine whether these up-
regulated gene sets could be employed to predict patient
outcome. Based on microarray screening and QPCR val-
idation (Fig. 2, Additional file 1: Table S2), 13 genes were
Fig. 4 PI3K and COX-2 involved phenotype changes of HUVECs. a Phase contrast micrographs of capillary-like tubular structures on Matrigel. Magnification,
x100. Graph bars showed the tube (left panel) and node (right panel) numbers of HUVECs treated with LY294002 or celecoxib in a co-culture system
(*P< 0.05). b Apoptotic percentage of HUVECs with LY294002 treatment in the co-culture system as measured by TUNEL assay. Green: TUNEL-positive
nuclei. Red: all nuclei. Bar graphs revealed the apoptotic percentage of HUVECs with LY294002 treatment after co-culture with CL1-5 cells (*P< 0.05). The
data are presented as the mean ± SD. Experiments were performed in triplicate. c Immunoblot of cleaved Caspase 3 and PARP of HUVECs; α-tubulin was
used as the loading control
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used to construct the prognostic gene signatures. In
these genes, two predicted the opposite clinical outcome
compared to our results (ITGB3 and PIK3R1) and thus
were not included in signature calculation. Using the
remaining 11 genes that were differentially expressed
after co-culture with cancer cells, we identified the gene
signatures to predict the overall survival and disease-free
survival of NSCLC patients. The 11-gene signature (12
probes from 11 genes) was identified based on the pa-
tient cohorts that had been published previously [25].
Detailed information on the probes, genes and risk score
formula for each gene signature is described in Add-
itional file 1: Table S3. Patients with a high expression
gene signature exhibited shorter median overall survival
and disease-free survival than patients with a low
expression gene signature (P = 0.0035 and P = 0.0026,
respectively; log rank test; Fig. 5a, b). Furthermore, we
selected the hub genes or more upstream genes to nar-
row down the gene number, which may be more applic-
able in clinical testing. The 5-gene signature (6 probes
from 5 genes) could more significantly predict overall
survival and disease-free survival (P = 0.0009 and P =
0.0016, respectively; log rank test; Fig. 5c, d). A multi-
variate Cox proportional hazards regression with covari-
ates of gender, age and stage was used to evaluate the
prognostic independence of gene signatures in the pub-
lished cohort (n = 293 in overall survival prediction; n =
278 in disease-free survival prediction). Except for the
11-gene set in disease-free survival, which was at the
borderline but still had a trend (P = 0.0521), the gene
Fig. 5 Kaplan–Meier estimates of NSCLC patient survival according to the stimulated endothelial cell gene signatures. a, b Kaplan-Meier estimates
of overall survival (n = 293) (a) and disease-free survival (n = 278) (b) of the subjects who were categorized based on the 11-gene signature
derived from the differentially expressed genes of HUVECs co-cultured with cancer cells. c, d Kaplan-Meier estimates of overall survival (n = 293)
(c) and disease-free survival (n = 278) (d) of the subjects who were categorized based on the 5-gene signature derived from the differentially
expressed genes of HUVECs co-cultured with cancer cells. The datasets were obtained from GSE30219. The survival curve was estimated by the
Kaplan-Meier method, and the log-rank test was performed to test the difference between the survival curves
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signatures were significant after considering the effects
of covariates (Table 2). The results indicated that the
gene signatures from cancer cell-stimulated endothelial
cells were correlated with extended overall survival and
disease-free survival in this published cohort.
Discussion
The tumour microenvironment is a complex network
composed of ECM, signalling molecules and different
types of stromal cells, including infiltrating immune
cells, cancer-associated fibroblasts, endothelial cells and
pericytes [31]. They all play their own role to support
tumour growth and restrict drugs from targeting the
tumour centre. During tumour progression, malignant
cells could also affect the microenvironment in many
ways to promote immune tolerance and angiogenesis
and sustain proliferative signalling. This influence makes
for favourable surroundings and benefits tumour sur-
vival, proliferation and metastasis in cancer development
[32]. In the present study, we found that the interaction
between endothelial and lung cancer cells changed the
HUVECs into a mesenchymal-like morphology, de-
creased the apoptotic percentage and increased the mi-
gration and tube forming ability of HUVECs. Using
microarrays and the DAVID bioinformatics database, we
identified several genes and signal transduction pathways
affected in HUVECs after co-culture with CL1-5 cells.
These differentially expressed genes were in accordance
with the biological phenotype changes of HUVECs. Ma-
nipulating PI3K and COX-2 activity by inhibitors could
reverse the tube formation ability and apoptotic resist-
ance of HUVECs. These results could help to identify
the feasible therapeutic target candidates for lung cancer
anti-angiogenesis therapy in the future.
Angiogenesis is crucial in normal physiology. However,
the imbalance of tumour angiogenesis activity is corre-
lated with malignant tumour growth and metastasis in
human cancers. To target angiogenesis in cancer ther-
apy, the characterization of tumour-derived endothelial
cells (TEC) from normal endothelial cells (NEC) is im-
portant. It has been shown that human hepatocellular
carcinoma-derived endothelial cells showed increased
proliferation, apoptosis resistance, migration and tube
formation ability compared with NEC [33]. A previous
study also showed that A549 conditioned medium (CM)
increased HUVECs cell survival and wound healing mi-
gration ability and decreased apoptosis via Akt activa-
tion. Knockdown of Akt or treatment with the PI3K
inhibitor wortmannin blocked A549 CM-induced cell
survival and the migration ability of HUVECs [34]. Al-
though cancer cells do not contact with endothelial cells
in the Transwell or CM co-culture system, cancer cells
can produce many growth factors and cytokines, such as
VEGF, basic fibroblast growth factor (bFGF) and IL-8, in
the medium to promote angiogenesis. VEGF is the most
potent angiogenic factor that can stimulate endothelial
cell proliferation and migration and decrease apoptosis
via VEGF-VEGF receptor 2 signalling pathway. It also in-
duces the adhesion molecules, ICAM1 and VCAM1, ex-
pression. In addition, bFGF not only modulates the
expression of integrins but also stimulates VEGF secre-
tion [35–37]. Interestingly, our data showed that some
of the above molecules are also upregulated in HUVECs
co-cultured with lung cancer cells.
In the present study, we also found that interaction
with lung cancer cells changed the HUVECs into a lon-
ger, mesenchymal-like morphology and increased the
migration, anti-apoptosis and tube formation ability
(Fig. 1). However, the proliferation rate did not change
in our system (data not shown). Furthermore, we identi-
fied that not only Akt but PI3K and Rac-1 were activated
in HUVECs after co-culture with CL1-5 cells (Fig. 3a, c).
In the previous report, the authors only investigated the
apoptosis resistance of NEC or A549 CM-treated
HUVECs by inoculating endothelial cells in culture
plates in serum starvation. Our data provided further
evidence that the interaction with cancer cells decreased
the apoptosis percentage of HUVECs on Matrigel, which
is more similar to ECM than the culture dish only. Fur-
thermore, the tube formation assay is closer to the
Table 2 Multivariate Cox regression analysis of two gene set
signatures for the overall survival of patients with NSCLC
Variable Hazard ratio 95% HR C.I. p-value
11-gene set, overall survival
Median of risk score 1.425 1.073 1.892 0.0143
Gender 1.460 0.926 2.300 0.1031
Age 1.037 1.022 1.052 <0.0001
Stage (0.1.2 vs. 3.4) 2.990 2.185 4.092 <0.0001
11-gene set, disease-free survival
Median of risk score 1.341 0.997 1.803 0.0521
Gender 1.485 0.930 2.371 0.0974
Age 1.036 1.020 1.051 <0.0001
Stage (0.1.2 vs. 3.4) 2.941 2.116 4.087 <0.0001
5-gene set, overall survival
Median of risk score 1.414 1.063 1.882 0.0172
Gender 1.455 0.923 2.293 0.1060
Age 1.037 1.022 1.052 <0.0001
Stage (0.1.2 vs. 3.4) 2.922 2.134 3.999 <0.0001
5-gene set, disease-free survival
Median of risk score 1.356 1.009 1.823 0.0435
Gender 1.489 0.933 2.375 0.0950
Age 1.036 1.021 1.051 <0.0001
Stage (0.1.2 vs. 3.4) 2.903 2.087 4.037 <0.0001
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process of angiogenesis in physiological conditions than
the wound healing assay to mimic vessel formation.
PI3K/Akt signalling elicits many downstream signalling
pathways, which are related to cell growth, cell survival,
cell cycle, apoptosis, cell motility, glucose metabolism and
angiogenesis [38]. Our study revealed that the interaction
with cancer cells increased the PI3K and Akt mRNA levels
of HUVECs, as well as their activities. This activation
turned on the downstream expression of genes such as β–
catenin and stimulated tube formation and apoptosis in-
duction (Figs. 1c, d and 2a). Previous studies reported that
β3 integrin induces calpain-dependent integrin cluster for-
mation, triggers Rac-1 activation and ultimately leads to
the formation of Rac-1-induced focal complexes. Rac-1 is
an important regulator of actin polymerization at the cell’s
leading edge. Knockdown of α-actinin impairs Rac-1 in-
duced dorsal stress fibre formation [39, 40]. Here, we
showed that the mRNA of integrin alpha V, integrin beta 3,
α-actinin and Rac-1, as well as the protein level of α-
actinin and active Rac-1 of HUVECs, were elevated after
interaction with cancer cells (Figs. 2b and 3b, c). These
changes resulted in filopodia and lamellipodia formation
and the increase of migration (Figs. 1b and 3d, e). COX-2,
IL-8, ICAM1 and VCAM1 are angiogenesis-related genes
[37]. IL-8 induces ICAM1, VCAM1 and COX-2 expression
[36]. Celecoxib decreases ICAM1 and VCAM1 expression
in HUVECs and inhibits HT29 cells’ adhesion to endothe-
lial cells [41]. Our data showed that the interaction of can-
cer and endothelial cells increases COX-2, IL-8, ICAM1
and VCAM1 mRNA levels of HUVECs (Fig. 2c). The in-
hibition of COX-2 by celecoxib prevented tube formation
when co-cultured with cancer cells (Fig. 4a).
COX-2 is overexpressed in many cancers and is associ-
ated with angiogenesis through the Rac/Cdc42 and PI3K-
Ras signalling pathway [42–44]. It has been shown that
COX-2 cross-talks with PI3K/Akt in epithelial ovarian can-
cer. The inhibition of COX-2 by aspirin and COX-2 siRNA
decreased Akt phosphorylation and the downstream signal-
ling pathway [45]. In angiogenesis, PI3K/Akt activation in-
duces VEGF production in cancer cells. Once VEGF binds
to the receptor, this binding also turns on the PI3K signal-
ling pathway in endothelial cells and causes actin
reorganization and cell migration and finally increases
angiogenesis. Here, we also showed that the mRNA level of
COX-2 and PI3K and the quantity of active PI3K protein
was increased in HUVECs after co-culture with cancer cells
(Figs. 2 and 3a). When we treated HUVECs with PI3K and
COX-2 inhibitors in the co-culture system, the angiogenesis
ability of HUVECs was reduced (Fig. 4). This indicated that
cancer cells could influence the endothelial cell phenotype
via the PI3K and COX-2 pathways, at least in our experi-
mental conditions. Taken together, COX-2 and PI3K could
not only be activated in cancer cells but also in endothelial
cells to induce angiogenesis through the interaction of
cancer and endothelial cells. This cross-talk creates a
microenvironment beneficial for tumour growth and finally
makes tumour cells malignant.
In clinical outcome analysis, tumour samples are typic-
ally collected to determine the gene expression profiles
and survival information. However, the tumour mass
was composed not only of cancer cells but also of other
surrounding cell types, including endothelial cells, im-
mune cells and stroma cells, which exist in the tumour
microenvironment [8]. Thus, we tried to use the differ-
entially expressed genes in HUVECs after co-culture
with cancer cells to predict the clinical outcome. Our
data indicated that these cancer cell-stimulated genes
could estimate patients’ overall survival and disease-free
survival (Fig. 5). This result suggested that these genes
were also important in cancer cells. The cause may be
the cross-talk between cancer and the microenviron-
ment as previously described. Furthermore, we also
compared the predictive power between our HUVECs
derived gene signatures and the published prognostic
gene signatures, 8-gene [46] and 7-gene [47], using the
same dataset GSE30219 as ours. To perform the com-
parisons appropriately, the 8- and 7-gene signatures
were employed to construct the risk score functions ac-
cording to our method and then subjected to overall sur-
vival analyses. Interestingly, the re-calculated log-rank
tests were more significant (P < 0.0001 and P = 0.0045,
respectively; Additional file 1: Figure S1a and S1b) com-
pared to the original studies (P = 0.000513 and P =
0.0071, respectively) in Kaplan-Meier estimates. The re-
sults also showed that both our gene signatures could
predict patient prognosis as well as the published 8-gene
signature did and better than the 7-gene signature in
early-stage lung adenocarcinoma (P < 0.0001 and P =
0.0029, respectively; log rank test; Additional file 1:
Figure S1c and S1d). It is worth mentioning that our 5-
gene signature has the fewest genes among the
signatures compared here. Therefore, taking the gene ex-
pression profile of endothelial cells into account may im-
prove the prognostic prediction.
Conclusions
The growth of new blood vessels is an essential process
for tumour progression, which makes angiogenesis a
favourable target in anti-cancer therapy. Among the fac-
tors that promote angiogenesis, the tumour microenviron-
ment plays a pivotal role, as described in this study and
others [33]. It is reasonable to propose that breaking down
the interaction or communication between cancer cells
and endothelial cells is an ideal approach for the treatment
of lung cancer patients. In this study, we found that COX-
2 and PI3K inhibitors could reverse the angiogenic pheno-
type of endothelial cells. Actually, several PI3K inhibitors
such as BKM120 and XL147 are under clinical
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development as a single agent therapy or in combination
with other drugs in NSCLC and other solid tumours [48–
51]. Therefore, the application of antitumour drugs with
COX-2 and/or PI3K inhibition activity or in combination
with the indicated inhibitors can be a feasible strategy for
developing cancer therapies in the future.
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